Harel Insurance Investments & Financial Services Ltd. Acquires 3,481 Shares of Johnson & Johnson $JNJ

Harel Insurance Investments & Financial Services Ltd. lifted its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 140.0% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,968 shares of the company’s stock after purchasing an additional 3,481 shares during the quarter. Harel Insurance Investments & Financial Services Ltd.’s holdings in Johnson & Johnson were worth $1,457,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of JNJ. Blueline Advisors LLC acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $25,000. Cresta Advisors Ltd. bought a new stake in shares of Johnson & Johnson during the fourth quarter worth $26,000. DecisionPoint Financial LLC increased its position in shares of Johnson & Johnson by 104.2% during the fourth quarter. DecisionPoint Financial LLC now owns 147 shares of the company’s stock worth $30,000 after acquiring an additional 75 shares in the last quarter. Family CFO Inc acquired a new stake in shares of Johnson & Johnson during the fourth quarter worth $31,000. Finally, Bay Harbor Wealth Management LLC lifted its position in Johnson & Johnson by 49.0% in the 4th quarter. Bay Harbor Wealth Management LLC now owns 149 shares of the company’s stock valued at $31,000 after acquiring an additional 49 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

JNJ has been the subject of a number of research analyst reports. Royal Bank Of Canada upped their target price on shares of Johnson & Johnson from $265.00 to $287.00 and gave the stock an “outperform” rating in a research note on Monday. Stifel Nicolaus set a $260.00 price target on Johnson & Johnson in a report on Wednesday. Wells Fargo & Company upped their price objective on Johnson & Johnson from $263.00 to $272.00 and gave the stock an “overweight” rating in a research report on Thursday. The Goldman Sachs Group reissued a “buy” rating and issued a $282.00 target price on shares of Johnson & Johnson in a research report on Thursday. Finally, TD Cowen boosted their target price on Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday. Nineteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $265.30.

Insider Buying and Selling at Johnson & Johnson

In other news, EVP Kathryn E. Wengel sold 10,000 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $241.15, for a total transaction of $2,411,500.00. Following the sale, the executive vice president owned 114,288 shares in the company, valued at $27,560,551.20. This represents a 8.05% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 0.16% of the stock is owned by company insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson beat Q2 estimates, posting earnings of $2.90 per share on revenue of $25.31 billion, helped by strong growth in Innovative Medicine products such as Darzalex, Tremfya and Spravato. Article Title
• Positive Sentiment: The company raised its 2026 guidance, signaling confidence in continued growth from its pharma pipeline and broader portfolio. Article Title
• Positive Sentiment: Analysts and commentary pointed to momentum beyond legacy drugs, with newer treatments and innovation in medtech and AI-enabled tools supporting the growth story. Article Title
• Neutral Sentiment: J&J also declared its quarterly dividend, reinforcing its appeal as a defensive income stock. Article Title
• Neutral Sentiment: Despite the earnings beat and higher outlook, some reports noted the stock slipped because the market had already priced in strong results and is still weighing mixed MedTech performance and ongoing litigation risk. Article Title

Johnson & Johnson Trading Up 1.1%

Shares of NYSE:JNJ opened at $249.70 on Friday. The company’s 50-day moving average price is $239.19 and its two-hundred day moving average price is $234.50. Johnson & Johnson has a one year low of $162.30 and a one year high of $269.43. The company has a debt-to-equity ratio of 0.46, a current ratio of 1.03 and a quick ratio of 0.77. The stock has a market capitalization of $601.08 billion, a PE ratio of 28.93, a price-to-earnings-growth ratio of 2.34 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Wednesday, July 15th. The company reported $2.90 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analysts’ expectations of $25.06 billion. Johnson & Johnson had a return on equity of 32.86% and a net margin of 21.48%.Johnson & Johnson’s revenue for the quarter was up 6.6% compared to the same quarter last year. During the same quarter last year, the company earned $2.77 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. On average, equities analysts forecast that Johnson & Johnson will post 11.67 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th will be paid a $1.34 dividend. This represents a $5.36 dividend on an annualized basis and a yield of 2.1%. The ex-dividend date is Tuesday, August 25th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.